A panelist discusses how financial burdens and insurance limitations impact chronic myeloid leukemia treatment decisions, with newer drugs like asciminib facing approval challenges despite recent FDA approval, while pharmacists can help overcome these obstacles by educating patients about assistance programs, advocating for access, and helping navigate the complex health care system to ensure sustainable long-term therapy options.